跳至主要内容
临床试验/NCT02618395
NCT02618395已完成1 期

Bioavailability Study of SPARC001 in Healthy Adult Volunteers

Sun Pharma Advanced Research Company Limited0 个研究点目标入组 18 人开始时间: 2015年12月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
18
主要终点
Maximum plasma hydrocodone and acetaminophen concentration (Cmax)

研究概览

简要总结

Bioavailability study

详细描述

Bioavailability, safety and tolerability

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult, male and female volunteers, 18 to 55 years of age
  • Body mass index (BMI) ≥18 to ≤30 kg/m2 at screening
  • Female subjects must have a negative serum pregnancy test
  • Medically healthy on the basis of medical history and physical examination

排除标准

  • Females who are pregnant, lactating, or likely to become pregnant during the study
  • Life-time history and/or recent evidence of alcohol
  • History of hypersensitivity to hydrocodone, acetaminophen or any component of the test and reference formulations
  • Subjects with any condition in which an opioid is contraindicated

研究组 & 干预措施

Treatment A

Experimental

干预措施: SPARC001A (Drug)

Treatment B

Experimental

干预措施: SPARC001B (Drug)

Treatment C

Experimental

干预措施: Reference001 - Hydrocodone (Drug)

结局指标

主要结局

Maximum plasma hydrocodone and acetaminophen concentration (Cmax)

时间窗: 17 days

次要结局

  • Treatment emergent adverse event(17 days)
  • AUC extrapolated to infinity (AUC0 ∞)(17 days)
  • Elimination half-life (t½)(17 days)
  • Time to Cmax (tmax)(17 days)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验